Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics analysis in suspected hereditary breast and ovarian cancer cases reveals novel candidate susceptibility factors.

NPJ breast cancer·2026
Same author

In-depth behavioral characterization of a rat model of Schaaf-Yang syndrome.

Scientific reports·2025
Same author

Updating descriptive sensory evaluation of chicken: proposing new protocols and statistical analysis.

Poultry science·2025
Same author

Online Training to Increase Genetic and Risk Literacy in Physicians Counseling Breast and Ovarian Cancer Patients for Genetic Testing.

Breast care (Basel, Switzerland)·2025
Same author

Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study.

BMC complementary medicine and therapies·2025
Same author

Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.

British journal of haematology·2025

Related Experiment Video

Updated: Jun 25, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Histopathological criteria and selection algorithms for BRCA1 genetic testing.

Dorothea Gadzicki1, Alexandra Schubert, Christine Fischer

  • 1Institute of Cell and Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Gadzicki.Dorothea@mh-hannover.de

Cancer Genetics and Cytogenetics
|February 14, 2009
PubMed
Summary

Identifying specific breast cancer features can help select patients for BRCA1 genetic testing. High-grade, triple-negative tumors with specific markers are more likely to be associated with BRCA1 mutations.

More Related Videos

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Related Experiment Videos

Last Updated: Jun 25, 2026

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Accurate diagnosis is crucial for targeted breast cancer treatment.
  • Identifying BRCA1 mutations aids in personalized therapy selection.
  • Morphological and immunohistochemical features may predict BRCA1 mutation status.

Purpose of the Study:

  • To evaluate the utility of histopathological features in identifying breast cancer patients who may benefit from BRCA1 genetic testing.
  • To correlate specific tumor characteristics with the presence of BRCA1 germline mutations.

Main Methods:

  • Retrospective analysis of 897 unselected breast cancer patients' tumor histopathology.
  • Reevaluation of tumor grade, subtype, estrogen (ER), progesterone (PR), and Her2/neu receptor status, p53, and Ki67.
  • Genetic testing for pathogenic BRCA1 germline mutations in selected patients.

Main Results:

  • 142 tumors met morphological criteria suggestive of BRCA1 mutation.
  • Pathogenic BRCA1 mutations were found in 39% of tested women with suggestive features.
  • BRCA1-associated tumors were predominantly high-grade, invasive-ductal, ER/PR/Her2/neu negative (triple-negative), with high p53 and Ki67 expression.

Conclusions:

  • Morphological and immunohistochemical features, particularly triple negativity and high-grade, can aid in selecting breast cancer patients for BRCA1 testing.
  • These markers can help optimize the use of genetic testing resources.
  • Further research can refine predictive models for BRCA1 mutations in breast cancer.